Treatment of thyroid cancer with the new oral agents

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2343-

  Galofre J C ^a   Gomez saez J M ^b   Escola, C A ^c   Anda, E ^d   Calleja, A ^a   Donnay, S ^e   Lucas martin, A ^f   Menendez torre E ^g   Pereg, V ^h   Perez corral B ⁱ   Santamaria J ^j   Riesco eizaguirre, G ^c   Zafon, C ^k  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g UNIVERSITY OF OVIEDO   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ Gerencia Regional de Salud de Castilla y León   (Spain)

^j HOSPITAL DE CRUCES   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOCORTICOID; PROTEIN TYROSINE KINASE INHIBITOR;

HEALTH CARE ORGANIZATION; HUMAN; HYPOTHYROIDISM; LETTER; PRIORITY JOURNAL; SPANISH SOCIETY OF MEDICAL ONCOLOGY; THYROID CANCER;

EID: 80053145315     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr409     Document Type: Letter

References (7)

1. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
2. Pacini F, Schlumberger M, Dralle H et al. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
3. Colomer R, Alba E, Gonzalez-Martin A et al. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology. Ann Oncol 2010; 21: 195-198.
4. Duntas LH, Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid 2010; 20: 1351-1358.
5. Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 2010; 31: 578-599.
6. Sherman SI, Wirth LJ, Droz JP et al. Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
7. Guedea F, Macia M, Sanchez Calzado JA et al. Treatment of cancer with drugs: a controversy (letter). Ann Oncol 2011; 22: 747-748.